InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$152.64

2026-10-16

Market Cap

$17.0B

Volume

1.3M

52-Wk High

$166.25

52-Wk Low

$81.22

Trailing PE

72.7

P/S

5.85

Gross Margin

52.1%

Net Margin

8.2%

ROE

3%

ROIC

3%

Piotroski

8/9

Altman Z

3.3

1-Yr Return

+62.5%

5-Yr Return

+88.8%

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

SectorHealthcareIndustryMedical - Diagnostics & ResearchExchangeNYSEMarket Cap$17.0BEmployees11,000 (SEC-filed)CEOPrahlad R. SinghIPO1965-07-06CountryUS

77 4th Avenue, Waltham, MA 02451 · Tel 781 663 6900 · revvity.com

INSIDERSTREET SCORE50 / 100Street mean $150.00 (4 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$1M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · RVTY +62.5% · S&P 500 +15.9% · spread +46.6pp

7 Years vs S&P 500 · RVTY +88.8% · S&P 500 +189.9% · spread -101.0pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE50of 100

Score Breakdown

Profitability	35/100
Growth	34/100
Momentum	66/100
Quality	70/100
Earnings Quality	69/100
Balance Sheet	55/100
Value	40/100
Risk (safety)	65/100
Overall	50.5/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
MEDP	84
EXAS	50
CRL	27
GH	42
ICLR	46
LH	62
RVTY	50

IS Score Trend — quarterly

13 quarters, 23 Q1 to 26 Q2. Peak 61 in 25 Q2, latest 50 — -11 since. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY50 / 100IS Score 50.5 / 100 · -10.6 from peak of 61

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 70 / 100 · Power +41 · 16 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 50 and price structure at 70 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 50.5	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 56 → 36 → 53 → 50	the direction matters more than the level
Technical vote share back above 50%	now 64%	price structure no longer broken

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)4 buys2026-05-04

Insider Buys (180d)0none disclosed

ETF Funds (30d)283 up / 221 downnet +62 funds

Institutions Added (13F)545managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Gonzales Anita	VP and CAO	2026-10-01	SELL	84	$0.01M	7,117
Krakowiak Maxwell	Please See Remarks	2026-09-21	SELL	1,631	$0.24M	14,781
Vohra Tajinder S	Please See Remarks	2026-09-16	SELL	7,330	$1.03M	6,635
Michas Alexis P	director	2026-08-25	GIFT	285	—	6,985
Goldberg Joel S	Please See Remarks	2026-08-14	GIFT	27,785	—	13,729
Goldberg Joel S	Please See Remarks	2026-08-14	GIFT	27,785	—	91,494
Singh Prahlad R.	director, Please See Remarks	2026-08-13	GIFT	7,636	—	105,676
Singh Prahlad R.	director, Please See Remarks	2026-08-13	GIFT	7,636	—	54,219

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	5	9,210	$1.3M	Counted
F — Tax withholding	1	33	$0.0M	None — compensation
G — Gifts	3	95,071	—	None
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$1.3M5 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Filed	Filer	Shares registered	Est. proceeds
2026-10-01	Gonzales Anita	84	$0.0M
2026-09-21	Krakowiak Maxwell	1,631	$0.2M
2026-09-16	Vohra Tajinder S	7,330	$1.0M
2026-07-20	Gonzales Anita	85	$0.0M
Trailing 12 mo	11 filings	56,170	$6M

Filed	Form	Reporting person	% of class	Shares
2026-10-07	SCHEDULE 13G/A	T. Rowe Price Associates, Inc.	11.80%	13.2M sh
2026-09-08	SCHEDULE 13G/A	T. Rowe Price Investment Management, Inc.	9.20%	10.3M sh
2026-08-14	SCHEDULE 13G/A	T. Rowe Price Investment Management, Inc.	16.40%	18.3M sh
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	7.44%	8.3M sh

Member	Chamber	Trade	Size band	Traded	Disclosed
Gilbert Cisneros	House	SELL	$15,001 - $50,000	2026-09-09	2026-10-13
Gilbert Cisneros	House	SELL	$15,001 - $50,000	2026-09-09	2026-10-12
Gilbert Cisneros	House	SELL	$1,001 - $15,000	2026-09-04	2026-10-13

House 12-Mo15 trades7 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)0

13F Shares0M0.0% of shares out

New / Closed0 / 0positions, QoQ

Increased / Reduced0 / 0positions, QoQ

Put/Call (13F)—option positions

Free Float91.9%102M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Wedge Capital Management L L P/Nc	176,660	$27M
Chapin Davis, Inc.	71,591	$11M
Family Legacy Financial Solutions,	54,208	$8M
Czech National Bank	32,061	$5M
Sivik Global Healthcare Llc	30,000	$5M
Assenagon Asset Management S.A.	23,685	$4M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.0%	$544M
VTI	0.0%	$544M
VSMPX	0.0%	$544M
VTSAX	0.0%	$544M
VFINX	0.0%	$448M
VFIAX	0.0%	$448M

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session55.6%2026-10-15

20-Day Avg52.3%50-day 51.1%

TrendRising20d vs 50d

By Market CenterQ: 56% · N: 55% · B: 55%latest session

Weekly Notional ($B)

Where RVTY Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Ubsa Ubs Ats	1.6M	56 sh
Sgmt Sigma X2	1.2M	43 sh
Ebxl Level Ats	1.0M	26 sh
Incr Intelligent Cross Llc	0.9M	44 sh
Mstx Ms Trajectory Cross (Ats-1)	0.9M	36 sh
Mlix Instinct X	0.9M	63 sh

Where a dollar of Revvity, Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
Other International	$2.7B	60%
UNITED STATES	$1.1B	25%
CHINA	$425M	9%
GERMANY	$178M	4%
UNITED KINGDOM	$127M	3%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

RVTY (live moat model)Peer median: MEDP · EXAS · CRL · GH · ICLR

Component scores from the live moat model. Peer median illustrative.

Moat score 55/100 — Narrow; primary source Efficient Scale.

Officer	Title
Prahlad R. Singh	Chief Executive Officer, President & Director
Joel S. Goldberg	Senior Vice President of Administration, General Counsel & Secretary
Maxwell Krakowiak	Senior Vice President & Chief Financial Officer
Miriame Victor	Senior Vice President & Chief Business Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

Quarterly EPS — Actual vs. Consensus

Beats (>2%)6 of 6recent quarters

Avg Surprise+6.8%

Next Report2026-11-03

Income Quality2.63OCF ÷ net income

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+1.2%	-13.5%	-16.9%	+0.2%	+3.7%
Gross profit	+14.6%	-22.8%	-24.9%	+0.0%	+14.6%
Operating income	+31.4%	-41.7%	-48.9%	+2.8%	-13.1%
Net income	+29.5%	-39.7%	-120.8%	-349.9%	-18.3%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	3.8	3.3	2.8	2.8	2.9
Cost of revenue	1.5	1.6	1.4	1.4	1.3
Gross profit	2.3	1.8	1.3	1.3	1.5
R&D expense	0.2	0.2	0.2	0.2	0.2
SG&A expense	0.7	0.8	0.7	0.7	0.9
Operating income	1.3	0.8	0.4	0.4	0.4
EBITDA	1.6	1.2	0.7	0.8	0.7
D&A	0.3	0.4	0.4	0.4	0.3
Pretax income	1.2	0.7	0.2	0.3	0.3
Income tax	0.3	0.1	0.0	0.0	0.0
Net income	0.9	0.6	-0.1	0.3	0.2
Diluted EPS ($)	8.08	4.50	-0.95	2.41	2.08
Diluted shares (M)	117	126	125	123	113

Operating CF$1B

CapEx$0B

Free cash flow$1B

SBC$0B

Buybacks$1B

Net cash change$-0B

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	0.5	0.9	1.2	0.9
ST investments	0.0	0.7	0.0	0.0
Receivables (net)	0.6	0.6	0.6	0.7
Total current assets	3.3	3.0	2.3	2.2
PP&E (net)	0.7	0.7	0.6	0.6
Goodwill + intangibles	9.9	9.6	9.1	9.0
Total assets	14.1	13.6	12.4	12.2
Accounts payable	0.3	0.2	0.2	0.2
Short-term debt	0.5	0.7	0.0	0.6
Deferred revenue	0.1	0.1	0.1	0.0
Total current liabilities	1.5	1.5	0.7	1.3
Long-term debt	3.9	3.2	3.2	2.8
Total liabilities	6.7	5.7	4.7	4.9
Shareholders' equity	7.4	7.9	7.7	7.3

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	0.5	0.2	0.3	0.2
D&A	0.4	0.4	0.4	0.4
Stock-based compensation	0.1	0.0	0.0	0.0
Working capital change	(0.3)	(0.4)	(0.0)	(0.1)
Operating cash flow	0.7	0.1	0.6	0.6
Capital expenditures	(0.1)	(0.1)	(0.1)	(0.1)
Investing cash flow	(0.1)	1.3	0.8	(0.0)
Buybacks	(0.1)	(0.4)	(0.4)	(0.8)
Dividends paid	(0.0)	(0.0)	(0.0)	(0.0)
Debt issuance / (repay)	(0.6)	(0.5)	(0.7)	(0.0)
Financing cash flow	(0.7)	(0.9)	(1.1)	(0.9)
Free cash flow	0.6	0.0	0.5	0.5

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY23	FY25	TTM
PROFITABILITY
ROE	17.0%	9.6%	3.2%	3%
ROA	8.0%	5.2%	1.9%	2.0%
ROIC	8.9%	3.8%	3.4%	2.9%
Gross margin	59.6%	48.1%	53.1%	52.1%
Operating margin	35.0%	14.5%	12.5%	12.3%
Net margin	24.6%	-4.3%	8.5%	8.2%
EBITDA margin	42.2%	25.9%	23.2%	26.3%
FCF margin	29.8%	0.4%	17.9%	—
VALUATION
P/E	27.34	18.71	45.32	72.7
P/B	3.53	1.70	1.51	2.4
P/S	5.70	4.88	3.84	5.85
P/FCF	19.13	1354.89	21.44	30.5
EV/EBITDA	18.00	22.26	17.69	25.2
EV/Revenue	6.73	5.77	4.74	6.6
Earnings yield	3.7%	5.3%	2.2%	1.39%
FCF yield	5.2%	0.1%	4.7%	3.28%

Ratio	FY21	FY23	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	2.01	2.07	1.68	1.80
Quick ratio	1.66	1.77	1.40	1.50
Debt / equity	0.72	0.52	0.48	0.46
Debt / assets	34.4%	30.0%	28.9%	27.7%
Net debt / EBITDA	2.75	3.45	3.39	3.02
Interest coverage	13.15	2.85	3.91	—

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY23	FY25	TTM
EFFICIENCY
Asset turnover	0.39	0.20	0.23	0.24
Receivables turnover	4.75	4.69	4.24	4.1
DSO (days)	77	78	86	89
DPO (days)	60	67	46	43
Cash conversion cycle	103	124	140	145
GROWTH (YoY)
Revenue growth	17.0%	-23.6%	4.9%	—
Net income growth	26.8%	16.5%	-20.4%	—
EPS growth	12.6%	19.4%	-13.5%	—
FCF growth	61.9%	-98.7%	-9.5%	—
PER SHARE ($)
EPS (diluted, TTM)	7.29	5.81	2.13	2.13
Book value / share	56.36	63.79	64.04	64.69
Revenue / share	34.92	22.29	25.23	26.06
FCF / share	10.41	0.08	4.51	5.01
Cash / share	4.76	12.99	8.13	9.15
SHAREHOLDER RETURN & SCORES
Buyback yield	0.3%	2.9%	7.5%	3.75%
Altman Z-Score	3.03	2.40	1.76	3.3
Piotroski F-Score	4	5	5	8/9
Beneish M-Score	-2.73	-1.99	-2.21	-2.62

Model	Score	Zone	Note
Piotroski F-Score	8 / 9	Strong
Altman Z-Score	3.3	Safe (>2.99)	Safe
Income quality	2.63	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.62	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.91
Interest burden	0.74
Operating margin	12.2%
Asset turnover	0.24×
Financial leverage	1.65×
= ROE	3%

Growth Quality (live)	Value
Revenue stability	0.74
Earnings stability	0.57
Earnings persistence	0.95
Revenue CAGR 3y	-3.6%
EPS CAGR 3y	-35.4%
FCF CAGR 3y	2.2%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield3.75%

Dividend Yield0.18%

Total Shareholder Return3.94%cash yield

SBC / Revenue0.8%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
MEDP	$17.3B	35.6	162%	17.2%	+24.7%	8/9	+18.7%
EXAS	$20.0B	-188.6	-9%	-9.8%	+17.7%	7/9	+119.7%
CRL	$14.5B	-62.0	-8%	-0.1%	-0.7%	4/9	+71.6%
GH	$21.3B	-45.4	172%	-35.9%	+42.7%	6/9	+135.1%
ICLR	$13.1B	39.7	3%	3.5%	+2.0%	6/9	—
LH	$25.8B	26.1	12%	8.0%	+6.4%	8/9	—
DGX	$25.9B	24.6	14%	10.5%	+9.9%	8/9	—
QGEN	$9.5B	23.7	12%	19.3%	+3.0%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

29 Analysts

Str Sell (0)Sell (0)Hold (14)Buy (15)Str Buy (0)

Mean Target (qtr)$150.004 targets

Target vs. Price-1.7%last-quarter mean

Next Report2026-11-03street $1.30

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$2.85B	$2.86B / $2.83B	$5.36	$5.40 / $5.35	9
FY2026	$2.93B	$2.96B / $2.91B	$5.32	$5.45 / $5.24	11
FY2027	$3.01B	$3.02B / $2.99B	$5.89	$5.92 / $5.83	9

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$160.00	+4.8%	1
Last Quarter	$150.00	-1.7%	4
Last Year	$120.73	-20.9%	22
All Time	$122.45	-19.8%	33

Rolling mean of published targets vs. last close $152.64. Aggregated from StreetInsider.

Third-Party Composite Rating

B-

DCF

3/5

ROE

2/5

ROA

4/5

Debt/Eq

2/5

P/E

1/5

P/B

3/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

RVTY +62.5% vs S&P 500 +15.9% — spread +46.6pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$151.44	+1.20	+0.79%	Above
SMA 50	$136.12	+16.52	+12.14%	Above
SMA 200	$109.11	+43.53	+39.90%	Above
EMA 9	$153.25	-0.61	-0.40%	Below
EMA 21	$149.42	+3.22	+2.15%	Above
EMA 50	$138.64	+14.00	+10.10%	Above
EMA 200	$115.39	+37.25	+32.28%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +4116 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%90

Momentum 25%50

Volume 20%75

Volatility 10%83

Patterns 15%50

This Week64% bullishof 11 price-based votes

4 Weeks Ago100%-36 pts since

12 Weeks Ago100%-36 pts since

ReadDeterioratingweek-over-week trajectory

Price vs SMA 20$151.44

Price vs SMA 50$136.12

Price vs SMA 200$109.11

EMA 9/21 Cross153.2/149.4

SMA 50/200Golden

ADX DirectionADX 41

Supertrend$141

Parabolic SAR$164

SMA Slope0.460

RSI59.2

Stochastic K/D33/40

StochRSI K/D7/13

Williams %R-70

CCI40

TSI vs Signal30.4

CMO18.3

ROC0.70%

OBV SignalAccum

Chaikin MF0.000

MFI57

Force Index0M

Elder Ray Bull6.07

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 40

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$153.47 / $158.10 / $161.50	S1 / S2	$150.07 / $145.44
Bollinger (20,2)	$143.45 – $159.43	Squeeze	ON
52-wk range	$81.22 – $166.25	Off 52-wk high	-8.2%
ATR (14)	$5.57 (3.6%)	Historical vol	32.4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+2.6%Jan55%

-1.2%Feb50%

+0.1%Mar48%

+0.4%Apr45%

+0.9%May60%

+0.8%Jun45%

+2.6%Jul60%

-0.4%Aug50%

+0.4%Sep60%

-0.5%Oct65%

+2.0%Nov80%

+1.4%Dec55%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	RVTY	S&P 500
Weekly volatility (σ, 1y)	5.81%	1.83%
Best / worst week (1y)	+21.3% / -12.2%	—
Max drawdown (5y, monthly)	-55.3%	—
1-week VaR (95%)	-7.6%	—
Beta (5y)	1.09	1.00

RVTY EQUITY WEATHER (LIVE)CLOUDY · +12

Trend+50

Momentum-1

Volume+26

Volatility-30

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 87 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+12.5+29.5 vs industry

Trend+50.2+57.5 vs industry

Momentum-0.8+26.2 vs industry

Volume+25.6+25.6 vs industry

Reading	RVTY	Medical - Diagnostics & Research n=227	Healthcare n=5,272	All US symbols n=70,435
Overall	+12.5	-17.0	-24.0	-20.5
Trend	+50.2	-7.2	-25.6	-21.3
Momentum	-0.8	-27.0	-28.5	-15.8
Volume	+25.6	+0.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Pillar (live disclosure scores)	Score
Environmental	61
Social	56
Governance	61
Composite ESG	59

Filed	8-K contents	Items
2026-08-04	Earnings Release; Other Events; Exhibits	2.02,8.01,9.01
2026-05-05	Earnings Release; Other Events; Exhibits	2.02,8.01,9.01
2026-05-01	Bylaws Amendment; Shareholder Vote; Exhibits	5.03,5.07,9.01
2026-02-02	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2026-01-13	Results of Operations and Financial Condition; Regulation FD Disclosur	2.02,7.01
2025-10-27	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-10-24	Departure/Election of Directors; Appointment of Officers	5.02
2025-07-28	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	19 rows · 2021-09-30 to 2026-08-04
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-28 to 2027-12-28
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	not present for this symbol
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-06-15 to 2026-10-01
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-04-30 to 2026-10-07
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Revvity, Inc. (RVTY)

Monthly Net Insider Flow (000 shares)

Signal Summary

Revvity, Inc. (RVTY)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

Revvity, Inc. (RVTY)

Where RVTY Trades in the Dark

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY)

Balance Sheet — Full

Cash Flow Statement — Full

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY)

Street Price Target — Trajectory

Third-Party Composite Rating

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY)

Family Scores (site weights)

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY)